Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients

Journal of International Medical Research

Volumn 30, Issue 6, 2002, Pages 584-590

  Lee, E ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Benign prostatic hyperplasia; Finasteride; Korea; Lower urinary tract symptoms; Tamsulosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HEADACHE; HUMAN; IMPOTENCE; KOREA; LEG EDEMA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; ORTHOSTATIC HYPOTENSION; POTENCY DISORDER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPERMATOZOON DENSITY; SYMPTOM; URINARY TRACT OBSTRUCTION; URINE FLOW RATE;

EID: 0036868264     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000203000606     Document Type: Review

References (22)

1. Lee E, Yoo K, Kim Y, Shin C: Prevalence of lower urinary tract symptoms in Korean Men in a community-based study. Eur Urol 1998; 33: 17 - 21.
2. Clifford GM, Logie J, Farmer RDT: How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 2000; 38 (Suppl 1): 48 - 53.
3. Bosch JL, Hop WC, Kirkels WJ, Schroder FH: The International Prostate Symptoms Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 622 - 630.
4. Isaacs JT, Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2 (Supp): 33 - 50.
5. Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ, del Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM: Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 1998; 159: 878 - 882.
6. Modsen FA, Bruskewitz RC: Clinical manifestation of benign prostatic hyperplasia. Urol Clin N Am 1995; 22: 291 - 298.
7. Lee E, Lee C: Clinical comparison of selective and non-selective α1A-adrenoceptor antogonists in benign prostatic hyperplasia: studies on tamulosin in a fixed-dose and terazosin in increasing doses. Br J Urol 1997; 80: 606 - 611.
8. Na YJ, Guo YL, Gu FL and the Chinese Tamsulosin Study Group: Clinical comparison of selective and non-selective aplha1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patient. J Med 1998; 29: 289 - 304.
9. Buzelin JM, Fonteyne E, Kontturri M, Witjes WP, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 597 - 605.
10. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Spekaman MJ, and the European Tamsulosin Study Group: Tamsulosin: 3-year lomg-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 1999; 36: 609 - 620.
11. Narayan P, LeporH: Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466 - 470.
12. Chapple CR: Selective α1-adrenoceptor antogonists in benign prostatic hyperpalsia: rationale and clinical experience. Eur Urol 1996; 29: 129 - 144.
13. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant α1-adrenoceptors Sto characterize subtype selectivity drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol Mol Pharmacol 1995; 288: 201 - 207.
14. Kawabe K: Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 1995; 76 (Supp 1): 63 - 67.
15. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypama AF, Abrams P: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 155 - 167.
16. Stoner E: The clinical effects of a Α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992; 147: 1298 - 1302.
17. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185 - 1191.
18. The Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291 - 299.
19. Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, et al: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperpalsia. Eur Urol 1992; 22: 271 -277.
20. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, et al: A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 1997; 79: 736 - 741.
21. Homma Y, Imajo C, Kawabe K, Aso Y: Responce criteria of treatment for benign prostatic hyperplasia. Int J Urol 1995; 2: 33 - 38.
22. Andersen JT: α1-blockers vs 5α-reductase inhibitors in benign prostatic hyperplasia: a comparative review. Drugs Aging 1995; 6: 387 - 396.